What does this research mean for the field?

Combination immunotherapy provides the greatest efficacy for metastatic melanoma and is the preferred first-line treatment regardless of BRAF status, though it carries higher toxicity compared to monotherapy. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

This analysis assesses the effectiveness of different therapeutic interventions for metastatic melanoma.

June 26, 2026Journal of Clinical Oncology

Comparative effectiveness of different interventions in metastatic melanoma: A network meta-analysis.

View Full Paper

Ask AI

Bookmark

Authors

SSSami SalahiaPioneer (United States)

Discussion

Member takes

Overview

Network meta-analysis examines efficacy of various therapies for metastatic melanoma, suggesting individualized treatment plans.

Key Points

This analysis assesses the effectiveness of different therapeutic interventions for metastatic melanoma.
Conducted a network meta-analysis of randomized controlled trials for metastatic melanoma treatments.
Primary outcomes included overall survival, progression-free survival, objective response rate, and adverse events.
Estimated hazard ratios and odds ratios with 95% confidence intervals.
Nivolumab plus ipilimumab achieved five-year overall survival of 55.7%, significantly better than monotherapy.
Combined BRAF-MEK therapy significantly improved progression-free survival (HR: 0.58) and overall survival (HR: 0.67) compared to BRAF alone.
Triple therapy showed longer progression-free survival (HR: 0.76) but higher adverse events rates.

Cite This Study

Sami Salahia (2026) studied this question.

synapsesocial.com/papers/6a3e169f030ad1a9b309062e https://doi.org/10.1200/jco.2026.44.19_suppl.294

View Full Paper

Ask AI

Bookmark

June 26, 2026Journal of Clinical Oncology

Comparative effectiveness of different interventions in metastatic melanoma: A network meta-analysis.

View Full Paper

Ask AI

Bookmark

Authors

SSSami SalahiaPioneer (United States)

Discussion

Member takes

Overview

Network meta-analysis examines efficacy of various therapies for metastatic melanoma, suggesting individualized treatment plans.

Key Points

This analysis assesses the effectiveness of different therapeutic interventions for metastatic melanoma.
Conducted a network meta-analysis of randomized controlled trials for metastatic melanoma treatments.
Primary outcomes included overall survival, progression-free survival, objective response rate, and adverse events.
Estimated hazard ratios and odds ratios with 95% confidence intervals.
Nivolumab plus ipilimumab achieved five-year overall survival of 55.7%, significantly better than monotherapy.
Combined BRAF-MEK therapy significantly improved progression-free survival (HR: 0.58) and overall survival (HR: 0.67) compared to BRAF alone.
Triple therapy showed longer progression-free survival (HR: 0.76) but higher adverse events rates.

Cite This Study

Sami Salahia (2026) studied this question.

synapsesocial.com/papers/6a3e169f030ad1a9b309062e https://doi.org/10.1200/jco.2026.44.19_suppl.294

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark